Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new ...

Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World Health Organization ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.

Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment ...

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.